Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of DNA ligation, the re-formation of a broken phosphodiester bond in the DNA backbone, carried out by DNA ligase. [GOC:ai]
Positive regulation of DNA ligation is a complex biological process that ensures the precise joining of DNA fragments. It plays a crucial role in various cellular processes, including DNA repair, replication, and recombination. This process is tightly regulated to maintain genomic integrity and prevent errors that can lead to mutations and disease. The key players in this process are DNA ligases, enzymes responsible for catalyzing the formation of phosphodiester bonds between the 5' phosphate and 3' hydroxyl termini of DNA strands. However, the activity of these ligases is modulated by various factors, including the presence of specific proteins and cofactors, the accessibility of the DNA substrate, and the cellular environment. Here is a detailed breakdown of the process:
1. **DNA Strand Break Recognition:** The process begins with the recognition of a DNA strand break. This break can arise from various sources, such as exposure to damaging agents like radiation or chemicals, or as a consequence of normal cellular processes. Once a break is detected, the appropriate repair machinery is recruited to the site.
2. **Recruitment of DNA Ligase:** DNA ligases are crucial for the final step of DNA repair, specifically the ligation of DNA ends. Several DNA ligases exist in cells, each with specific roles and substrate preferences. For instance, DNA ligase IV is essential for non-homologous end joining (NHEJ), a major pathway for repairing double-strand breaks, while DNA ligase I is primarily involved in base excision repair (BER) and replication.
3. **Activation of DNA Ligase:** DNA ligases often require activation to be fully functional. This activation may involve the interaction with specific proteins, the binding of cofactors like ATP, or the presence of other DNA repair factors.
4. **Ligation of DNA Ends:** Once activated, the DNA ligase binds to the broken DNA ends and catalyzes the formation of a phosphodiester bond between the 5' phosphate and the 3' hydroxyl group. This reaction requires ATP as an energy source and involves a series of enzymatic steps. First, the ligase adenylates itself, attaching an AMP molecule to its active site. Then, the activated ligase transfers the AMP to the 5' phosphate of the DNA strand break. Finally, the ligase forms a phosphodiester bond between the 5' phosphate and the 3' hydroxyl group of the other DNA strand, releasing AMP and completing the ligation.
5. **Regulation of DNA Ligase Activity:** The activity of DNA ligases is tightly regulated to ensure accurate and efficient repair. This regulation can involve a variety of mechanisms:
* **Protein-protein interactions:** DNA ligases often interact with other proteins involved in DNA repair, like the XRCC4 protein in NHEJ. These interactions help to recruit the ligase to the correct location and ensure its proper function.
* **Post-translational modifications:** DNA ligases can be modified by phosphorylation or ubiquitination, which can alter their activity or stability.
* **Cellular environment:** Factors like the availability of ATP, the concentration of specific cofactors, and the overall cellular redox state can influence DNA ligase activity.
6. **Quality Control:** After ligation, the newly formed DNA strand is often subject to quality control mechanisms. These mechanisms ensure that the repair process is accurate and that the DNA sequence is not altered.
In summary, positive regulation of DNA ligation is an essential process for maintaining genomic integrity and preventing the accumulation of mutations. This process involves the coordinated action of multiple proteins and enzymes, and its regulation ensures the accurate and efficient repair of DNA damage.'
"
Protein | Definition | Taxonomy |
---|---|---|
Protein mono-ADP-ribosyltransferase PARP3 | A protein mono-ADP-ribosyltransferase PARP3 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9Y6F1] | Homo sapiens (human) |
DNA repair protein RAD51 homolog 1 | A DNA repair protein RAD51 homolog 1 that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
High mobility group protein B1 | A high mobility group protein B1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P09429] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
salicylic acid | Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL). | monohydroxybenzoic acid | algal metabolite; antifungal agent; antiinfective agent; EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor; keratolytic drug; plant hormone; plant metabolite |
diflunisal | diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position. Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN. | monohydroxybenzoic acid; organofluorine compound | non-narcotic analgesic; non-steroidal anti-inflammatory drug |
pj-34 | PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties. | phenanthridines; secondary carboxamide; tertiary amino compound | angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent |
3-aminobenzoic acid | 3-aminobenzoic acid : An aminobenzoic acid carrying an amino group at position 3. 3-aminobenzoic acid: RN given refers to parent cpd | aminobenzoic acid | |
glycyrrhizic acid | glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid. | enone; glucosiduronic acid; pentacyclic triterpenoid; tricarboxylic acid; triterpenoid saponin | EC 3.4.21.5 (thrombin) inhibitor; plant metabolite |
5-hydroxyindole | hydroxyindoles | human metabolite | |
4-Methoxybenzamide | benzamides | ||
methyl tryptophan, (l-trp)-isomer | |||
methotrexate | dicarboxylic acid; monocarboxylic acid amide; pteridines | abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent | |
3-chloro-1-(2-chlorophenyl)-4-(4-morpholinyl)pyrrole-2,5-dione | maleimides | ||
3-chloro-1-(3,4-dichlorophenyl)-4-(4-morpholinyl)-1h-pyrrole-2,5-dione | 3-chloro-1-(3,4-dichlorophenyl)-4-(4-morpholinyl)-1H-pyrrole-2,5-dione: an inhibitor of RAD51 that disrupts homologous recombination in human cells; structure in first source | ||
rucaparib | AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source | azepinoindole; caprolactams; organofluorine compound; secondary amino compound | antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor |
latonduine a | latonduine A: structure in first source | ||
veliparib | benzimidazoles | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | |
olaparib | cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines | antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | |
niraparib | 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide : A member of the class of indazoles that is 2H-indazole substituted by 4-(piperidin-3-yl)phenyl and aminocarbonyl groups at positions 2 and 7, respectively. It is a potent PARP1 inhibitor with IC50 of 3.2 nM. | benzenes; indazoles; piperidines; primary carboxamide | antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor |
niraparib | niraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy. niraparib: structure in first source | 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide | antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; radiosensitizing agent |
xav939 | XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group. XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source | (trifluoromethyl)benzenes; thiopyranopyrimidine | tankyrase inhibitor |
bmn 673 | talazoparib: inhibits both PARP1 and PARP2; structure in first source | ||
me0328 | ME0328: inhibits ARTD3; structure in first source |